Table 2.
Clinicopathologic features of study subjects
| Variable | CTC (liver cancer) |
p-valuea) | CTC (HCC) |
p-valuea) | ||
|---|---|---|---|---|---|---|
| Absent (n=15) | Present (n=14) | Absent (n=12) | Present (n=11) | |||
| Age (yr) | 59.80±13.58 | 55.93±11.63 | 0.418 | 56.25±12.74 | 55.09±10.00 | 0.812 |
| Sex | ||||||
| Male | 13 (50.0) | 13 (50.0) | 0.584 | 11 (52.4) | 10 (47.6) | > 0.999 |
| Female | 2 (66.7) | 1 (33.3) | 1 (50.0) | 1 (50.0) | ||
| Histologic type | ||||||
| HCC | 12 (52.2) | 11 (47.8) | 0.719 | 12 (52.2) | 11 (47.8) | - |
| CC | 1 (50.0) | 1 (50.0) | - | - | ||
| Combined HCC-CC | 0 | 1 (100) | ||||
| Metastatic cancer | 2 (50.0) | 1 (100) | - | - | ||
| Size (cm) | 11.40±5.33 | 9.20±3.25 | 0.195 | 10.92±5.80 | 9.33±3.23 | 0.432 |
| T stageb) | ||||||
| T1 | 2 (100) | 0 | 0.002 | 2 (100) | 0 | 0.010 |
| T2 | 0 | 0 | 0 | 0 | ||
| T3 | 11 (47.8) | 12 (52.2) | 10 (47.6) | 11 (52.3) | ||
| T4 | 0 | 1 (100) | 0 | 0 | ||
| Stageb) | ||||||
| I | 2 (100) | 0 | 0.405 | 2 (100) | 0 | 0.370 |
| II | 0 | 0 | 0 | 0 | ||
| III | 8 (47.1) | 9 (52.9) | 7 (46.7) | 8 (53.3) | ||
| IVA | 0 | 1 (100) | 0 | 0 | ||
| IVB | 3 (50.0) | 3 (50.0) | 3 (50.0) | 3 (50.0) | ||
| Multiplicityb) | ||||||
| Absent | 5 (45.5) | 6 (54.5) | 0.691 | 5 (55.6) | 4 (44.4) | > 0.999 |
| Present | 8 (53.3) | 7 (46.7) | 7 (50.0) | 7 (50.0) | ||
| Portal vein invasionb) | ||||||
| Absent | 8 (72.7) | 3 (27.3) | 0.055 | 8 (80.0) | 2 (20.0) | 0.036 |
| Present | 5 (33.3) | 10 (66.7) | 4 (30.8) | 9 (69.2) | ||
| AFP | ||||||
| Normal | 5 (50.0) | 5 (50.0) | > 0.999 | 4 (57.0) | 3 (43.0) | 0.066 |
| Elevated | 8 (50.0) | 8 (50.0) | 8 (50.0) | 8 (50.0) | ||
Values are presented as mean±standard deviation or number (%). CTC, circulating tumor cell; HCC, hepatocellular carcinoma; CC, cholangiocarcinomas; AFP, α-fetoprotein.
a)
Spearman’s rank correlation analysis,
b)
These data were not available for three patients with metastatic carcinoma.